F-1: Evaxion Registers 769K ADSs for EIB Resale

Evaxion A/S files an F-1 registration statement for the resale of 769,000 American Depositary Shares by the European Investment Bank, stemming from a debt settlement.

Summary

• The F-1 registration statement covers the resale of up to 38,450,000 ordinary shares, represented by 769,000 American Depositary Shares (ADSs), by the European Investment Bank (EIB).
• These shares are issuable upon the exercise of warrants received by EIB as part of a debt settlement agreement that closed on July 11, 2025.
• Evaxion A/S will not receive any proceeds from the sale of ADSs by the selling shareholder, but may receive up to DKK 9,612,500 (approximately $1,498,378) if the warrants are exercised.
• On September 25, 2025, MSD exercised an option on vaccine candidate EVX-B3, providing Evaxion with a $7.5 million cash payment and eligibility for up to $592 million in future development, regulatory, and sales milestone payments, plus royalties.
• Evaxion reported new two-year Phase 2 clinical efficacy data for its personalized cancer vaccine EVX-01 in metastatic melanoma, demonstrating a 75% Objective Response Rate (ORR) with 12 out of 16 patients showing objective clinical responses, including four complete responses, as of October 17, 2025.
• The company launched an improved AI-Immunology platform with a new automated vaccine design module on October 8, 2025.
• Evaxion raised $7.2 million on October 30, 2025, comprising $4.5 million from an at-the-market (ATM) offering and $2.7 million from investor warrant exercises, extending its cash runway to the second half of 2027.
• A new AI-designed precision cancer vaccine candidate, EVX-04, was added to the R&D pipeline on November 3, 2025.
• Dr. Helen Tayton-Martin was elected to the board on April 30, 2025, and will become Chief Executive Officer effective November 24, 2025, succeeding interim CEO Dr. Birgitte Rn, who will remain Chief Scientific Officer.
• Thomas Schmidt has been appointed permanent Chief Financial Officer.
• Evaxion regained compliance with Nasdaq's continued listing requirements as of February 14, 2025, after previously falling below the stockholders' equity requirement.

Sentiment

Score: 8

Explanation: The filing presents a highly positive outlook, driven by a significant partnership with MSD, strong Phase 2 clinical trial results for EVX-01, successful capital raises, and improved financial stability, including regaining Nasdaq compliance and extending the cash runway. While the company still operates at a loss and faces inherent biotech risks, the recent achievements represent substantial progress and de-risking.

Positives

• MSD exercised an option on vaccine candidate EVX-B3, resulting in a $7.5 million upfront payment and potential future development, regulatory, and sales milestone payments of up to $592 million, plus royalties.
• The Phase 2 trial for personalized cancer vaccine EVX-01 in metastatic melanoma patients showed an unprecedented 75% Objective Response Rate (ORR), with 12 out of 16 patients achieving objective clinical responses and four complete responses.
• Successfully raised $7.2 million through an at-the-market offering and warrant exercises, extending the cash runway to the second half of 2027.
• Expanded the R&D pipeline with a new AI-designed precision cancer vaccine candidate, EVX-04, targeting non-conventional ERV tumor antigens.
• Launched an improved AI-Immunology platform with a new automated vaccine design module, enhancing target discovery and vaccine design capabilities.
• Regained full compliance with Nasdaq's listing rules as of February 14, 2025, removing the immediate delisting risk.
• Finalized a debt settlement agreement with the European Investment Bank (EIB), cancelling EUR 3.5 million of a EUR 7 million loan in exchange for warrants.

Negatives

• The company will not receive direct proceeds from the resale of shares by the selling shareholder (EIB), only from the potential exercise of warrants (up to approximately $1.498 million).
• Evaxion has incurred significant losses since its inception and anticipates continued significant losses for the foreseeable future.
• Reported a net loss of $(1,789) thousand for the nine months ended September 30, 2025, and $(6,411) thousand for the six months ended June 30, 2025.
• The company has a limited operating history and no vaccine developed using its technology has yet been approved.
• Requires substantial additional financing to achieve its goals, and a failure to obtain this capital could force delays, scale-backs, or cessation of product development activities.
• The sale of a substantial amount of ordinary shares (including those from EIB warrants) in the public market could adversely affect the prevailing market price of the company's shares and result in dilution to existing shareholders.
• Uncertainty regarding the company's classification as a Passive Foreign Investment Company (PFIC) for U.S. federal income tax purposes, which could lead to adverse tax consequences for U.S. Holders.

Risks

• The company is a clinical-stage TechBio company with only product candidates currently in clinical development.
• It has a limited operating history and no vaccine has been approved using its technology, and none may ever be approved.
• The company is dependent upon successfully concluding partnerships to advance product candidates and monetize assets.
• Significant losses have been incurred since inception, and significant losses are anticipated for the foreseeable future.
• Substantial additional financing will be required to achieve goals; failure to obtain capital could force delays, scale-backs, or cessation of product development or operations.
• Difficulties in managing company development and expansion could disrupt operations.
• Dependence on the success of product candidates, which may not be successful in nonclinical studies or clinical trials, receive regulatory approval, or be successfully commercialized.
• Clinical drug development involves a lengthy and expensive process with uncertain outcomes, and substantial delays may be encountered.
• Interim and preliminary data from clinical trials may change as more patient data become available and are subject to audit and verification.
• Pharmaceutical product development is inherently uncertain, with no guarantee of marketing approval for any product candidates.
• Intense competition in the biotechnology and pharmaceutical industries means competitors may discover, develop, or commercialize products faster or more successfully.
• Global conflicts (e.g., Ukraine/Russia, Middle East) could adversely affect business and results of operations.
• Failure to meet Nasdaq's continued listing requirements could result in a delisting of ADSs.
• Product candidates may not work as intended, cause undesirable side effects, or have other properties that could delay or prevent regulatory approval.
• Regulatory approval processes are lengthy, time-consuming, and inherently unpredictable.
• Future partners may not be able to obtain regulatory approval or effectively commercialize products derived from product candidates.
• Reliance on third-parties to manufacture preclinical, clinical, and commercial supplies, and for the conduct of studies and trials; failure of these third parties could impede regulatory approval.
• Future partners may encounter difficulties in manufacturing, product release, shelf life, testing, storage, supply chain management, and/or shipping.
• Certain product candidates may be uniquely manufactured for each patient, posing difficulties in production scaling.
• Inadequate efforts to obtain, maintain, protect, defend, and/or enforce intellectual property could hinder market competitiveness.
• Potential involvement in lawsuits to protect or enforce intellectual property or defend against third-party claims.
• The sale of a substantial amount of ordinary shares represented by ADSs, including those from EIB warrants, could adversely affect the prevailing market price and cause dilution.
• Potential classification as a Passive Foreign Investment Company (PFIC) for U.S. federal income tax purposes, leading to adverse U.S. federal income tax consequences for U.S. Holders.

Future Outlook

The company intends to use any proceeds received from warrant exercises to advance its preclinical and clinical pipeline, and for continuing operating expenses and working capital. It anticipates continued significant losses for the foreseeable future and will require substantial additional financing to achieve its goals. The recent capital raise has extended the cash runway to the second half of 2027.

Management Comments

• "We believe we are the first in the world to demonstrate a correlation between the predictive power of AI and clinical response in patients, as evidenced by a clear association between AI-Immunology predictions and progression free survival in metastatic melanoma cancer patients."
• "AI-Immunology allows for fast and effective discovery, design and development of novel vaccines and offers a strong value proposition to both existing and potential pharma partners."
• "Our recently announced significantly expanded partnership with MSD validates this approach and confirms the value of the AI-Immunology platform seen from an external perspective."
• "Evaxion is committed to transforming patients lives by providing innovative and targeted treatment options through AI-Immunology. Our purpose is saving and improving lives with AI-Immunology."

Industry Context

Evaxion A/S operates in the highly competitive and innovative TechBio sector, leveraging Artificial Intelligence (AI) for the discovery and development of novel vaccines for cancer and infectious diseases. The company's expanded partnership with MSD and the positive Phase 2 clinical data for EVX-01 underscore the growing industry trend towards personalized medicine and the integration of AI/machine learning to accelerate drug development, reduce costs, and improve clinical outcomes. These developments position Evaxion as a notable player in the evolving landscape of AI-driven therapeutic and prophylactic vaccine solutions.

Comparison to Industry Standards

• The company states it is "the first in the world to demonstrate a correlation between the predictive power of AI and clinical response in patients," specifically in metastatic melanoma cancer patients, suggesting a pioneering role in AI-Immunology validation.
• The 75% Objective Response Rate (ORR) in the Phase 2 trial for EVX-01 in advanced melanoma is described as "unprecedented clinical efficacy data," implying a superior outcome compared to typical results for similar treatments in this indication.

Management Changes

Corporate Governance

Related Party Transactions

• The European Investment Bank (EIB) is the selling shareholder, having received warrants for 38,450,000 ordinary shares as part of a debt settlement agreement on July 11, 2025, which cancelled EUR 3.5 million of a EUR 7 million loan.
• MSD GHI (Global Health Institute) participated in the public offering on January 31, 2025.
• MSD (Merck & Co., Inc.) exercised an option on vaccine candidate EVX-B3 on September 25, 2025, leading to a $7.5 million cash payment and potential future milestones.

Stakeholder Impact

• **Shareholders**: Potential for significant dilution from the exercise of warrants by EIB and other outstanding warrants, as well as future capital raises. However, recent positive clinical data, the MSD partnership, and improved financial metrics could positively impact share value. U.S. Holders face potential adverse tax consequences if the company is classified as a PFIC.
• **Employees**: Management changes, including a new permanent CEO and CFO, may bring strategic shifts. Employee warrant programs serve as incentives.
• **Creditors**: The debt settlement with EIB reduced the outstanding loan by EUR 3.5 million, improving the company's debt profile.
• **Customers/Patients**: Progress in developing novel AI-designed vaccines for cancer and infectious diseases offers potential new treatment options and improved patient outcomes.

Next Steps

• MSD will assume full responsibility and carry all costs for the further development of the EVX-B3 vaccine.
• Advance the company's preclinical and clinical pipeline.
• Continue to manage operating expenses and working capital.
• Dr. Helen Tayton-Martin will become Chief Executive Officer effective November 24, 2025.
• The company will be under a Nasdaq Mandatory Panel Monitor for a period of one year from February 14, 2025.

Key Dates

Recommendation

The company has demonstrated significant positive momentum, including a major partnership with MSD that provides substantial non-dilutive funding and external validation of its AI-Immunology platform. The 75% Objective Response Rate in the Phase 2 EVX-01 trial for metastatic melanoma is a highly compelling clinical outcome, suggesting strong potential for this personalized cancer vaccine. Furthermore, the company has successfully raised capital, extended its cash runway to H2 2027, and resolved its Nasdaq compliance issue, significantly de-risking the investment. While still a clinical-stage company with inherent risks and ongoing losses, these recent achievements position Evaxion for strong future growth, making it an attractive opportunity for long-term investors.

Keywords

AI-Immunology, personalized cancer vaccine, EVX-01, EVX-B3, EVX-04, TechBio, biotechnology, pharmaceutical, clinical-stage, vaccine development, oncology, infectious diseases, SEC filing, F-1, ADSs, warrants, debt settlement, Nasdaq